查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970854

妊娠相关高血压诊断市场－全球产业规模、份额、趋势、机会、预测：按产品、最终用户、地区和竞争对手划分，2021-2031年

Preeclampsia Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球子痫前症诊断市场预计将从 2025 年的 8.4903 亿美元成长到 2031 年的 11.0947 亿美元，复合年增长率为 4.56%。

此领域涵盖用于识别妊娠高血压疾病的医疗设备和检测套组（例如血压监测仪、尿蛋白尿液检查试剂盒和胎盘生长因子生物标记）。推动该领域成长的主要因素是全球孕产妇风险因素（例如肥胖、慢性高血压和高龄生产）发生率的上升，这些风险因素需要严格的产前监测。此外，将早期风险评估通讯协定纳入常规产前检查以及政府主导的降低孕产妇死亡率的倡议，也为市场扩张提供了基础性支撑，而与具体的技术趋势无关。

市场概览
预测期 2027-2031
市场规模：2025年 8.4903亿美元
市场规模：2031年 11.0947亿美元
复合年增长率：2026-2031年 4.56%
成长最快的细分市场 消耗品
最大的市场 北美洲

然而，特定生物标记检测的成本效益和可近性方面存在着许多阻碍市场成长的重大障碍，尤其是在疾病负担沉重的资源匮乏地区。这种差距限制了有效筛检工具的广泛应用，而这些工具对于预防严重临床后果至关重要。妊娠毒血症基金会2024年的资料显示，妊娠毒血症及相关高血压疾病每年在全球造成约7.6万名孕产妇和50万名婴儿死亡，凸显了这些诊断缺口的严重性。

市场驱动因素

基于生物标记的诊断检测技术的进步是推动市场发展的关键因素，它将治疗标准从被动反应转向预测性风险分层。业界正迅速采用评估血管新生因子（例如 sFlt-1/PlGF 比值）的检测方法，这些方法与传统的血压测量和蛋白尿尿液检查相比，具有更高的预测准确性。例如，LabCorp 于 2024 年 5 月发布的「早期妊娠毒血症筛检测试」表明，该新方法在检测早期风险方面灵敏度高达 90%，显着优于传统的评估方法。这种诊断准确性将促使其在临床工作流程中得到更广泛的应用，并加快介入速度，从而直接提升诊断设备製造商的收入。

同时，由于子痫前症发病率的上升，市场也不断扩张。这一趋势与高龄生产以及育龄妇女中肥胖、糖尿病等慢性疾病的日益普遍密切相关。根据美国早产儿基金会（March of Dimes）于2024年11月发布的《2024年报告卡》，2022年至2023年间，美国先兆子痫的发病率增长超过10%，因此需要对不断扩大的高危险群进行频繁的诊断监测。 2024年5月，《Femtech Insider》杂誌发表了一篇题为《Labcorp推出妊娠毒血症风险筛检新测试》的报导，强调了这项疾病的广泛影响。报导指出，目前美国每25例妊娠中就有1例受到妊娠毒血症的影响，凸显了精准诊断解决方案的紧迫性。

市场挑战

在资源匮乏的环境中，专业生物标记检测的高昂成本和有限的普及程度是限制全球妊娠毒血症诊断市场发展的主要阻碍因素。儘管发展中地区对严格的产前监测有着极高的临床需求，但资金和基础设施的限制往往阻碍了先进诊断设备和检查室分析技术的应用。这种差距使得市场参与企业难以在高需求地区企业发展，从而有效地将潜在市场规模限制在主要高所得国家。因此，疾病盛行率与经济购买力之间的差距减缓了这些关键工具在全球的普及。

这些经济壁垒直接影响产业收入，因为全球仍有相当一部分患者无法获得医疗保健服务。进入这些市场的困难导致潜在销售量成长大幅下降，因为企业无法在临床负担最重的地区扩大规模。世界卫生组织（世卫组织）2024年报告显示，约92%的孕产妇死亡发生在低收入和中低收入国家。这项数据凸显了严重的市场失衡，显示对诊断工具需求最高的地区最难取得这些工具，阻碍了整个产业的扩张。

市场趋势

人工智慧驱动的预测分析的整合正在从根本上改变市场格局，它能够处理复杂的生理数据，从而实现非侵入性、高精度的筛检方法。这一趋势超越了传统的蛋白质检测，利用机器学习演算法分析视网膜血管变化等新型输入数据，实现疾病的早期检测。这些数位化工具增强了筛检的扩充性，提供了超越传统风险因素评估的预测能力，并加速了软体产品作为医疗设备的开发。正如 Medscape 2024 年 3 月号报导的《人工智慧识别妊娠毒血症的视网膜生物标记》中所述，新近评估的人工智慧框架「DVT-Net」在妊娠早期和中期预测先兆子痫的准确率达到了 0.813，显着提高了症状出现前识别高风险患者的能力。

同时，远端和居家监测解决方案的推广应用，正将诊断监测的范围从医院扩展到其他场所，尤其是在高风险产后管理方面。这项转变涉及使用连网血压监测仪和远端医疗平台，从而实现持续的生理监测，确保及时应对可能被忽略的高血压高峰。事实证明，该策略对于降低与再次入院相关的产妇发病率以及在产后关键阶段维持护理的连续性至关重要。根据发表在2024年8月《妇产科计画》（The ObG Project）上的一篇题为「远距血压监测计画对妊娠高血压患者产后护理的影响」的论文，参与远距高血压管理计画与产后6週内再次入院率的显着降低相关，与标准照护相比，调整后的风险比为0.78。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：妊娠相关高血压诊断的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品类别（设备、耗材、其他）
    • 依最终使用者（医院、专科诊所、诊断中心等）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美妊娠相关高血压诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲妊娠相关高血压诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区妊娠相关高血压诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲妊娠相关高血压诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲妊娠相关高血压诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球妊娠相关高血压诊断市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Diabetomics Inc.
  • DRG INSTRUMENTS GMBH
  • F. Hoffmann-La Roche Ltd
  • Afekta Technologies Ltd.
  • MOMM Diagnostics GmbH
  • PerkinElmer Inc.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24595

The Global Preeclampsia Diagnostics Market is projected to expand from USD 849.03 Million in 2025 to USD 1109.47 Million by 2031, registering a compound annual growth rate of 4.56%. This sector comprises medical devices and laboratory assays-such as blood pressure monitors, proteinuria testing kits, and placental growth factor biomarkers-developed to identify hypertensive disorders during pregnancy. Growth is largely fueled by the increasing global incidence of maternal risk factors, including obesity, chronic hypertension, and advanced maternal age, which demand strict prenatal monitoring. Additionally, the incorporation of early risk assessment protocols into routine antenatal care and government-led initiatives to lower maternal mortality rates provide foundational support for market expansion, independent of specific technological trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 849.03 Million
Market Size 2031USD 1109.47 Million
CAGR 2026-20314.56%
Fastest Growing SegmentConsumables
Largest MarketNorth America

However, market growth faces a substantial obstacle regarding the affordability and accessibility of specific biomarker tests in low-resource regions, where the burden of disease is frequently the heaviest. This inequality restricts the broad implementation of effective screening tools needed to prevent severe clinical outcomes. Data from the Preeclampsia Foundation in 2024 indicates that approximately 76,000 mothers and 500,000 infants die globally each year due to preeclampsia and associated hypertensive disorders, highlighting the critical nature of these diagnostic gaps.

Market Driver

Technological progress in biomarker-based diagnostic assays acts as a pivotal market driver, shifting the standard of care from reactive management toward predictive risk stratification. The industry is rapidly adopting assays that evaluate angiogenic factors, such as the sFlt-1/PlGF ratio, which provide predictive accuracy superior to traditional blood pressure and proteinuria checks. For instance, Labcorp's May 2024 announcement regarding their 'First Trimester Preeclampsia Screening Test' noted that the new method achieved a sensitivity of up to 90% in detecting early-onset risk, significantly outclassing conventional assessments. This level of diagnostic precision promotes broad uptake within clinical workflows to enable prompt interventions, thereby directly boosting revenue for diagnostic manufacturers.

Concurrently, the expanding addressable market is bolstered by the rising incidence of hypertensive disorders during pregnancy. This trend correlates closely with advanced maternal age and the increasing prevalence of chronic conditions, such as obesity and diabetes, among women of reproductive age. According to the March of Dimes '2024 Report Card' released in November 2024, the national rate of pre-pregnancy hypertension rose by over 10% between 2022 and 2023, requiring frequent diagnostic monitoring for an enlarging high-risk demographic. The extensive reach of the condition is highlighted by a May 2024 Femtech Insider article, 'Labcorp Introduces New Screening Test for Preeclampsia Risk,' which states that roughly one in 25 pregnancies in the United States is currently impacted by preeclampsia, underscoring the urgent need for accurate diagnostic solutions.

Market Challenge

The prohibitive cost and limited availability of specialized biomarker tests in low-resource environments represent a primary constraint on the Global Preeclampsia Diagnostics Market. Although the clinical necessity for strict prenatal monitoring is intense in developing regions, financial and infrastructural shortcomings often prevent the acquisition of advanced diagnostic devices and laboratory assays. This disparity precludes market participants from securing a presence in high-volume geographies, effectively confining the total addressable market to primarily high-income nations. As a result, the disconnect between disease prevalence and economic purchasing power retards the global adoption rate of these vital tools.

This economic hurdle directly affects industry revenue by leaving a substantial segment of the global patient population without access to care. The inability to penetrate these markets leads to a considerable loss in potential volume growth, as manufacturers are unable to scale operations in areas where the clinical burden is most severe. According to a 2024 report by the World Health Organization, approximately 92% of all maternal deaths took place in low- and lower-middle-income countries. This statistic illustrates a profound market imbalance, wherein the regions with the greatest implied need for diagnostics possess the least capacity to access them, thereby suppressing overall industry expansion.

Market Trends

The integration of AI-driven predictive analytics is fundamentally transforming the market landscape by facilitating non-invasive, highly accurate screening methods that process complex physiological data. This trend transcends standard protein assays by utilizing machine learning algorithms to examine novel inputs, such as retinal vascular changes, for earlier disease detection. These digital tools enhance the scalability of screening and provide predictive capabilities that exceed traditional risk factor assessments, encouraging the creation of software-as-a-medical-device products. As reported by Medscape in the March 2024 article 'AI Identifies Retinal Biomarkers for Preeclampsia,' a newly evaluated AI framework called DVT-Net achieved an accuracy level of 0.813 for early prediction during the first and second trimesters, significantly improving the identification of at-risk patients prior to symptom onset.

Simultaneously, the expansion of remote and home-based monitoring solutions is extending diagnostic supervision beyond hospital settings, specifically for high-risk postpartum management. This shift entails the use of connected blood pressure devices and telehealth platforms that enable continuous physiological tracking, ensuring timely responses to hypertensive spikes that might otherwise go unnoticed. This strategy is proving essential for lowering maternal morbidity rates linked to hospital readmissions and maintaining care continuity during the critical postpartum phase. According to an August 2024 article by The ObG Project titled 'How Does Remote BP Monitoring Program Impact Postpartum Care for Those with Hypertensive Disorders of Pregnancy?,' participation in a remote hypertension management program was linked to a significantly reduced six-week postpartum readmission rate, demonstrating an adjusted risk ratio of 0.78 compared to standard care.

Key Market Players

  • Diabetomics Inc.
  • DRG INSTRUMENTS GMBH
  • F. Hoffmann-La Roche Ltd
  • Afekta Technologies Ltd.
  • MOMM Diagnostics GmbH
  • PerkinElmer Inc.
  • Sera Prognostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Preeclampsia Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preeclampsia Diagnostics Market, By Product

  • Instruments
  • Consumables
  • Others

Preeclampsia Diagnostics Market, By End User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

Preeclampsia Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preeclampsia Diagnostics Market.

Available Customizations:

Global Preeclampsia Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preeclampsia Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Consumables, Others)
    • 5.2.2. By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Preeclampsia Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preeclampsia Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Preeclampsia Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Preeclampsia Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe Preeclampsia Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preeclampsia Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France Preeclampsia Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Preeclampsia Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Preeclampsia Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Preeclampsia Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific Preeclampsia Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Preeclampsia Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India Preeclampsia Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Preeclampsia Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Preeclampsia Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Preeclampsia Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa Preeclampsia Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Preeclampsia Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Preeclampsia Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Preeclampsia Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America Preeclampsia Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Preeclampsia Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Preeclampsia Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Preeclampsia Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Preeclampsia Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Diabetomics Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. DRG INSTRUMENTS GMBH
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Afekta Technologies Ltd.
  • 15.5. MOMM Diagnostics GmbH
  • 15.6. PerkinElmer Inc.
  • 15.7. Sera Prognostics, Inc.
  • 15.8. Siemens Healthineers AG
  • 15.9. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer